Literature DB >> 1847283

Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone.

D Clerc, C Brousse, X Mariette, P Bennet, M Bisson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847283      PMCID: PMC1004336          DOI: 10.1136/ard.50.1.67-b

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  3 in total

1.  Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for psoriatic arthropathy.

Authors:  P J Wallis; K S Ryatt; T J Constable
Journal:  Ann Rheum Dis       Date:  1989-03       Impact factor: 19.103

Review 2.  Progress in the treatment of cytomegalovirus pneumonia.

Authors:  I Frank; H M Friedman
Journal:  Ann Intern Med       Date:  1988-11-15       Impact factor: 25.391

3.  Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate.

Authors:  C W Carson; G W Cannon; M J Egger; J R Ward; D O Clegg
Journal:  Semin Arthritis Rheum       Date:  1987-02       Impact factor: 5.532

  3 in total
  4 in total

Review 1.  Methotrexate-related pulmonary complications in rheumatoid arthritis.

Authors:  P Barrera; R F Laan; P L van Riel; P N Dekhuijzen; A M Boerbooms; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1994-07       Impact factor: 19.103

2.  Factors Associated with Pneumocystis jirovecii Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study.

Authors:  Shin-Ichiro Ohmura; Yoichiro Homma; Takayuki Masui; Toshiaki Miyamoto
Journal:  Intern Med       Date:  2021-09-11       Impact factor: 1.282

3.  Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate.

Authors:  M J van der Veen; A van der Heide; A A Kruize; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1994-04       Impact factor: 19.103

Review 4.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.